Skip Ribbon Commands
Skip to main content
Sign In
Skip to main content Open accessibility information page
Alert
On January 16, 2024, Governor Phil Murphy signed the New Jersey Data Privacy Law, P.L. 2023, c. 266. The law went into effect on January 15, 2025. Please click on this Frequently Asked Questions link to learn more about the new law and your rights under it.
Alert
On January 8, 2024, Governor Murphy signed into law P.L. 2023, c. 237, which, among other things: amended the Contractors’ Business Registration Act (“CBRA,” formerly the “Contractors’ Registration Act”), N.J.S.A. 56:8-136 et seq., and created the “Home Improvement and Home Elevation Contractor Licensing Act,” N.J.S.A. 45:5AAA-1 et seq. For more information on the registration requirements for contractors and businesses under these laws, click here.
Alert
On July 10, 2024, Governor Murphy signed into law the Real Estate Consumer Protection Enhancement Act, P.L. 2024, c.32, which, among other things, requires sellers of residential property located in New Jersey to use the "Seller's Property Condition Disclosure Statement" ("Disclosure Statement," questions 1 through 108).

Additionally, on July 3, 2023, Governor Murphy signed into law P.L. 2023, c.93, which, among other things, requires sellers of all real property located in New Jersey to make certain additional disclosures concerning flood risks on the "Disclosure Statement." On July 15, 2024, the Division published a "Flood Risk Addendum" to the Disclosure Statement (questions 109 through 117), which includes the additional disclosures concerning flood risks.

As a result of these two laws, effective August 1, 2024:
  • Sellers of residential property must complete the Disclosure Statement (questions 1 through 108). A copy of the Disclosure Statement is available here; and
  • All sellers of real property, both residential and non-residential, must complete the Flood Risk Addendum to the Disclosure Statement (questions 109 through 117). A copy of the Flood Risk Addendum is available here.

The Division has created an instruction sheet with additional information regarding the use of these forms. The forms linked above supersede any forms previously posted by the Division, including, but not limited to, the "Amended Disclosure Statement" posted on December 21, 2023.

Press Release

For Immediate Release:
May 19, 2014

Office of The Attorney General
John J. Hoffman, Acting Attorney General

Division of Consumer Affairs
Steve C. Lee, Acting Director

Division of Law
Jeffrey S. Jacobson, Director
  For Further Information and Media Inquiries:
Jeff Lamm
Neal Buccino
(973) 504-6327
In Case You Missed It: New Jersey Consumer Affairs Director Urges Healthcare Professionals to Use the New Jersey Prescription Monitoring Program in the Fight Against Prescription Drug Abuse

NEWARK - New Jersey Division of Consumer Affairs Acting Director Steve C. Lee, in an op-ed published today in The Star-Ledger, called upon New Jersey's healthcare community to embrace the New Jersey Prescription Monitoring Program (NJPMP) in order to help fight the nationwide epidemic of prescription drug abuse. The op-ed was published in connection with National Prevention Week, an observance dedicated to increasing public awareness of substance abuse issues.

The op-ed can be read in full at NJ.com.

It states:

    "Last year, a Mercer County physician logged onto the New Jersey Prescription Monitoring Program database to search prescriptions written in his name. The results shocked him. The doctor discovered his identity had been stolen in a massive prescription fraud scheme.
    "One or more criminals had illegally obtained his prescription pad and were using it to forge prescriptions for oxycodone, a widely abused narcotic painkiller. Within a month, 12 fraudulent patient names had been used to obtain 1,300 pills, sellable on the streets for $25,000. If this physician hadn't searched NJPMP records, this illegal opiate distribution scheme might never have been detected."
    The op-ed notes that slightly more than 20 percent of New Jersey's eligible prescribers and pharmacists have registered to use the NJPMP. "Given that the program is relatively new, that's an impressive adoption rate … [b]ut with the urgency of our drug-abuse crisis, New Jersey's health care community can and must do better."

The op-ed goes on to describe the steps that the Division of Consumer Affairs has taken to increase the rate at which prescribers and pharmacists bring the NJPMP into their daily practice, and notes that New Jersey's healthcare community must fully commit to the prescription-tracking database in order to help reduce drug diversion and opiate abuse.

For more information on the New Jersey Division of Consumer Affairs' initiative to halt the diversion and abuse of prescription drugs, view the Division's NJPMP website, and the Division's Project Medicine Drop website.

Follow the Division of Consumer Affairs on Facebook , and check our online calendar of upcoming Consumer Outreach events.

###

Last Modified: 2/25/2015 7:15 AM

Division

Department

State

Legal

RSS

Sign up for New Jersey Division of Consumer Affairs RSS feeds to get the latest information. You can select any category that you are interested in, and any time the website is updated you will receive a notification.

More information about RSS feeds.

Copyright © 2022 State of New Jersey.

OPRA Logo